Large cell neuroendocrine carcinoma of the lung: A retrospective analysis of 144 surgical cases

Giulia Veronesi, Uliano Morandi, Marco Alloisio, Alberto Terzi, Giuseppe Cardillo, Pierluigi Filosso, Federico Rea, Francesco Facciolo, Giuseppe Pelosi, Sara Gandini, Francesco Calabrò, Christian Casali, Giuseppe Marulli, Lorenzo Spaggiari

Research output: Contribution to journalArticle

Abstract

Objective: Large cell neuroendocrine carcinoma of the lung are considered aggressive. However, reported prognoses are heterogeneous and the optimum treatment remains undefined. We retrospectively evaluated outcomes in a series of patients with a pathological diagnosis of large cell neuroendocrine lung carcinoma, who underwent lung resection. We also assessed the utility of chemotherapy in a small subgroup. Patients and methods: The clinical records of 144 consecutive patients were reviewed in a multicenter study. Survival times, assessed from the day of surgery until death or most recent follow-up, were estimated by the Kaplan-Meier method, and compared by the log rank test. Results: There were 117 men and 27 women of median age 63 years. Twelve wedge resections, 3 segmentectomies, 95 lobectomies, 7 bilobectomies and 24 pneumonectomies were performed. Induction chemotherapy was given in 21 and postoperative chemotherapy in 24. Pathologically, 73 (50%) were stage I, 29 (20%) stage II, 40 (28%) stage III and 2 stage IV. Postoperative mortality was 2.8% and morbidity 26%. Overall 5-year survival was 42.5%: 52% for stage I, 59% for stage II and 20% for stage III (p = 0.001 log-rank test on Kaplan-Meier curves). A trend to better outcome was associated with preoperative or postoperative chemotherapy in stage I disease (p = 0.077) compared to no chemotherapy. The response rate to induction chemotherapy was 80% in the 15 patients with data available. Conclusion: large cell neuroendocrine carcinoma of the lung are confirmed as aggressive but are also chemosensitive. Our experience suggests that chemotherapy may improve prognosis in stage I disease.

Original languageEnglish
Pages (from-to)111-115
Number of pages5
JournalLung Cancer
Volume53
Issue number1
DOIs
Publication statusPublished - Jul 2006

Fingerprint

Neuroendocrine Carcinoma
Large Cell Carcinoma
Drug Therapy
Lung
Induction Chemotherapy
Survival
Segmental Mastectomy
Pneumonectomy
Kaplan-Meier Estimate
Ambulatory Surgical Procedures
Multicenter Studies
Morbidity
Mortality

Keywords

  • Lung cancer
  • Neuroendocrine tumors
  • Prognosis
  • Surgery

ASJC Scopus subject areas

  • Oncology

Cite this

Large cell neuroendocrine carcinoma of the lung : A retrospective analysis of 144 surgical cases. / Veronesi, Giulia; Morandi, Uliano; Alloisio, Marco; Terzi, Alberto; Cardillo, Giuseppe; Filosso, Pierluigi; Rea, Federico; Facciolo, Francesco; Pelosi, Giuseppe; Gandini, Sara; Calabrò, Francesco; Casali, Christian; Marulli, Giuseppe; Spaggiari, Lorenzo.

In: Lung Cancer, Vol. 53, No. 1, 07.2006, p. 111-115.

Research output: Contribution to journalArticle

Veronesi, Giulia ; Morandi, Uliano ; Alloisio, Marco ; Terzi, Alberto ; Cardillo, Giuseppe ; Filosso, Pierluigi ; Rea, Federico ; Facciolo, Francesco ; Pelosi, Giuseppe ; Gandini, Sara ; Calabrò, Francesco ; Casali, Christian ; Marulli, Giuseppe ; Spaggiari, Lorenzo. / Large cell neuroendocrine carcinoma of the lung : A retrospective analysis of 144 surgical cases. In: Lung Cancer. 2006 ; Vol. 53, No. 1. pp. 111-115.
@article{53658dfaacc543a0ac6fcc3fbf334128,
title = "Large cell neuroendocrine carcinoma of the lung: A retrospective analysis of 144 surgical cases",
abstract = "Objective: Large cell neuroendocrine carcinoma of the lung are considered aggressive. However, reported prognoses are heterogeneous and the optimum treatment remains undefined. We retrospectively evaluated outcomes in a series of patients with a pathological diagnosis of large cell neuroendocrine lung carcinoma, who underwent lung resection. We also assessed the utility of chemotherapy in a small subgroup. Patients and methods: The clinical records of 144 consecutive patients were reviewed in a multicenter study. Survival times, assessed from the day of surgery until death or most recent follow-up, were estimated by the Kaplan-Meier method, and compared by the log rank test. Results: There were 117 men and 27 women of median age 63 years. Twelve wedge resections, 3 segmentectomies, 95 lobectomies, 7 bilobectomies and 24 pneumonectomies were performed. Induction chemotherapy was given in 21 and postoperative chemotherapy in 24. Pathologically, 73 (50{\%}) were stage I, 29 (20{\%}) stage II, 40 (28{\%}) stage III and 2 stage IV. Postoperative mortality was 2.8{\%} and morbidity 26{\%}. Overall 5-year survival was 42.5{\%}: 52{\%} for stage I, 59{\%} for stage II and 20{\%} for stage III (p = 0.001 log-rank test on Kaplan-Meier curves). A trend to better outcome was associated with preoperative or postoperative chemotherapy in stage I disease (p = 0.077) compared to no chemotherapy. The response rate to induction chemotherapy was 80{\%} in the 15 patients with data available. Conclusion: large cell neuroendocrine carcinoma of the lung are confirmed as aggressive but are also chemosensitive. Our experience suggests that chemotherapy may improve prognosis in stage I disease.",
keywords = "Lung cancer, Neuroendocrine tumors, Prognosis, Surgery",
author = "Giulia Veronesi and Uliano Morandi and Marco Alloisio and Alberto Terzi and Giuseppe Cardillo and Pierluigi Filosso and Federico Rea and Francesco Facciolo and Giuseppe Pelosi and Sara Gandini and Francesco Calabr{\`o} and Christian Casali and Giuseppe Marulli and Lorenzo Spaggiari",
year = "2006",
month = "7",
doi = "10.1016/j.lungcan.2006.03.007",
language = "English",
volume = "53",
pages = "111--115",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Large cell neuroendocrine carcinoma of the lung

T2 - A retrospective analysis of 144 surgical cases

AU - Veronesi, Giulia

AU - Morandi, Uliano

AU - Alloisio, Marco

AU - Terzi, Alberto

AU - Cardillo, Giuseppe

AU - Filosso, Pierluigi

AU - Rea, Federico

AU - Facciolo, Francesco

AU - Pelosi, Giuseppe

AU - Gandini, Sara

AU - Calabrò, Francesco

AU - Casali, Christian

AU - Marulli, Giuseppe

AU - Spaggiari, Lorenzo

PY - 2006/7

Y1 - 2006/7

N2 - Objective: Large cell neuroendocrine carcinoma of the lung are considered aggressive. However, reported prognoses are heterogeneous and the optimum treatment remains undefined. We retrospectively evaluated outcomes in a series of patients with a pathological diagnosis of large cell neuroendocrine lung carcinoma, who underwent lung resection. We also assessed the utility of chemotherapy in a small subgroup. Patients and methods: The clinical records of 144 consecutive patients were reviewed in a multicenter study. Survival times, assessed from the day of surgery until death or most recent follow-up, were estimated by the Kaplan-Meier method, and compared by the log rank test. Results: There were 117 men and 27 women of median age 63 years. Twelve wedge resections, 3 segmentectomies, 95 lobectomies, 7 bilobectomies and 24 pneumonectomies were performed. Induction chemotherapy was given in 21 and postoperative chemotherapy in 24. Pathologically, 73 (50%) were stage I, 29 (20%) stage II, 40 (28%) stage III and 2 stage IV. Postoperative mortality was 2.8% and morbidity 26%. Overall 5-year survival was 42.5%: 52% for stage I, 59% for stage II and 20% for stage III (p = 0.001 log-rank test on Kaplan-Meier curves). A trend to better outcome was associated with preoperative or postoperative chemotherapy in stage I disease (p = 0.077) compared to no chemotherapy. The response rate to induction chemotherapy was 80% in the 15 patients with data available. Conclusion: large cell neuroendocrine carcinoma of the lung are confirmed as aggressive but are also chemosensitive. Our experience suggests that chemotherapy may improve prognosis in stage I disease.

AB - Objective: Large cell neuroendocrine carcinoma of the lung are considered aggressive. However, reported prognoses are heterogeneous and the optimum treatment remains undefined. We retrospectively evaluated outcomes in a series of patients with a pathological diagnosis of large cell neuroendocrine lung carcinoma, who underwent lung resection. We also assessed the utility of chemotherapy in a small subgroup. Patients and methods: The clinical records of 144 consecutive patients were reviewed in a multicenter study. Survival times, assessed from the day of surgery until death or most recent follow-up, were estimated by the Kaplan-Meier method, and compared by the log rank test. Results: There were 117 men and 27 women of median age 63 years. Twelve wedge resections, 3 segmentectomies, 95 lobectomies, 7 bilobectomies and 24 pneumonectomies were performed. Induction chemotherapy was given in 21 and postoperative chemotherapy in 24. Pathologically, 73 (50%) were stage I, 29 (20%) stage II, 40 (28%) stage III and 2 stage IV. Postoperative mortality was 2.8% and morbidity 26%. Overall 5-year survival was 42.5%: 52% for stage I, 59% for stage II and 20% for stage III (p = 0.001 log-rank test on Kaplan-Meier curves). A trend to better outcome was associated with preoperative or postoperative chemotherapy in stage I disease (p = 0.077) compared to no chemotherapy. The response rate to induction chemotherapy was 80% in the 15 patients with data available. Conclusion: large cell neuroendocrine carcinoma of the lung are confirmed as aggressive but are also chemosensitive. Our experience suggests that chemotherapy may improve prognosis in stage I disease.

KW - Lung cancer

KW - Neuroendocrine tumors

KW - Prognosis

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=33744795445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744795445&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2006.03.007

DO - 10.1016/j.lungcan.2006.03.007

M3 - Article

C2 - 16697073

AN - SCOPUS:33744795445

VL - 53

SP - 111

EP - 115

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -